VCNX - Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application | Benzinga

Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting

New ActivMAb^® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference

ROCHESTER, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present data on a new ActivMAb^® application on September 28^th and an update on the Phase 1b/2 pepinemab study in patients with PDAC on September 29^th.

Vaccinex will provide an overview of the design and enrollment for the pancreatic ductal adenocarcinoma (PDAC) study (NCT05102721). Currently, seven patients are enrolled. Treatment has been well-tolerated by these patients to date and a mixed response with some lesions showing radiologic partial and even complete response has been observed in one patient. The trial, which employs a Bayesian Optimal Interval (BOIN) Design in the Phase 1b segment and a Simon two stage assessment in the Phase 2 segment, is expected to enroll up to 40 patients. The study rationale builds on safety and efficacy data from the CLASSICAL-Lung study of pepinemab and avelumab and the observation that pepinemab appears to modulate the tumor microenvironment by increasing effector cell infiltration and reducing immune suppression, rendering "cold" tumors such as PDAC to become "hot". The study is being conducted with grant support from the Gateway Discovery Award (Conquer Cancer Foundation / ASCO).

Full story available on Benzinga.com